Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 32 peer-reviewed journal articles Updated
Ophthalmology · Autosomal Dominant Optic Atrophy

What is the Risk of Total Blindness with ADOA?

At a Glance

Total blindness is extremely rare in classic Autosomal Dominant Optic Atrophy (ADOA). While the condition causes a gradual decline in central vision and can lead to legal blindness, the vast majority of patients retain usable peripheral vision and maintain independent mobility.

If you have just been diagnosed with Autosomal Dominant Optic Atrophy (ADOA), your first and most urgent question is likely, “Will I go completely blind?” The short and reassuring answer is almost certainly no. Total blindness—meaning the complete inability to see any light or shapes—is extremely rare in classic ADOA. While the condition does cause progressive vision changes, the vast majority of people with ADOA retain useful peripheral (side) vision throughout their entire lives.

Total Blindness vs. Legal Blindness

When doctors talk about vision loss in ADOA, it is crucial to understand the difference between “total blindness” and “legal blindness.”

  • Total Blindness: Also called “no light perception,” this means the eyes cannot detect any light at all. This outcome is exceptionally rare in classic ADOA.
  • Legal Blindness: This is a medical and legal designation often defined by having a central visual acuity (sharpness) of 20/200 or worse in your better eye, or a significantly narrowed visual field. Some individuals with ADOA do eventually meet the criteria for legal blindness [1][2][3]. However, even if someone is considered legally blind, they typically still have meaningful, usable vision. Because ADOA largely spares peripheral vision [4][5][6], you will likely still be able to see obstacles, navigate your neighborhood safely, and walk around independently.

In ADOA, vision loss is primarily driven by the degeneration of retinal ganglion cells [2][7][8]. These are specialized cells in the eye that rely heavily on healthy mitochondria (the “power plants” of the cells) to function. The OPA1 gene mutation causes these power plants to fail, leading to gradual damage. This process typically affects your central vision—the sharp, detailed vision used for reading, recognizing faces, or seeing fine color differences (such as telling blue from yellow) [5][9][10]—while leaving your side vision mostly intact.

Classic ADOA vs. ADOA Plus

It is also helpful to understand why doctors often specify “classic” ADOA.

  • Classic ADOA: This refers to symptoms that are strictly limited to the eyes, causing isolated vision changes [11][12].
  • ADOA Plus (ADOA+): This is a variant that occurs in about 20% of people with OPA1 mutations [13][14][15]. In ADOA+, the mitochondrial damage affects other parts of the body, leading to additional symptoms like hearing loss, muscle weakness, or balance issues [13][11][16]. If you ever notice new neurological or hearing changes, it is important to report them to your care team.

The Path of Vision Loss

The reality of visual prognosis in classic ADOA is defined by significant variability [17][18][19]. It is described as a slowly progressive optic neuropathy, meaning the optic nerve gradually loses function over many years [20][21][22].

While vision changes usually begin in early childhood [20][22][23], the rate at which vision declines can range from completely stable to more severe [24][25][26]. Importantly, some patients maintain relatively good visual function well into late middle age [4][6][27].

Doctors track this progression by looking at structural changes in your eye. Specifically, they use imaging tests like Optical Coherence Tomography (OCT) to measure the thickness of the Retinal Nerve Fiber Layer (RNFL) and the Ganglion Cell Complex (GCC) [28][9][24]. The thinning of these specific layers is a reliable clinical biomarker that helps doctors understand how the disease is affecting your vision over time [28][29][6].

Your exact experience will depend on various factors, including the specific type of genetic mutation you carry [13][19][18]. Even within the same family, where relatives carry the exact same genetic mutation, the severity and progression of vision loss can vary widely [30][31][32].

Moving Forward

Living with ADOA requires adapting to changes in visual acuity, but it does not mean living in total darkness. Because your central vision is most affected, you can benefit tremendously from low-vision aids—such as specialized magnifiers, screen-reading software, and high-contrast tools—which can make the prospect of reduced vision much more manageable. Understanding that your peripheral vision will likely remain intact is a crucial piece of knowledge that can help you plan for the future with less fear and more practical preparation.

Common questions in this guide

Will I go completely blind from ADOA?
Total blindness, which means having no light perception at all, is exceptionally rare in classic ADOA. While the condition causes progressive vision changes, the vast majority of people retain useful peripheral vision throughout their entire lives.
What is the difference between total blindness and legal blindness in ADOA?
Total blindness means the eyes cannot detect any light or shapes. Legal blindness is a clinical designation that occurs when central visual sharpness drops to 20/200 or worse. Many people with ADOA who are legally blind still have meaningful, usable side vision.
Why does ADOA cause vision loss?
Vision loss is primarily caused by an OPA1 gene mutation that damages the mitochondria in your eye's retinal ganglion cells. As these cells lose function, it causes a gradual decline in central vision and the ability to distinguish certain colors.
What is ADOA Plus?
ADOA Plus occurs in about 20 percent of people with the OPA1 gene mutation. Unlike classic ADOA which only affects the eyes, ADOA Plus can also cause additional neurological symptoms like hearing loss, muscle weakness, or balance issues.
How does my eye doctor track the progression of ADOA?
Eye doctors use a non-invasive imaging test called Optical Coherence Tomography (OCT) to measure the thickness of the Retinal Nerve Fiber Layer and Ganglion Cell Complex. The thinning of these layers helps doctors monitor how the disease is affecting your vision over time.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my current RNFL and GCC thickness measurements, and how have they changed over time?
  2. 2.Based on my specific OPA1 mutation, am I at risk for ADOA Plus symptoms like hearing loss, and should we be monitoring for them?
  3. 3.At what point in my disease progression should I seek a referral to a low-vision rehabilitation specialist?
  4. 4.Are there specific types of visual field tests that you recommend for monitoring my peripheral vision?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Do Supplements Like CoQ10 or NAD+ Work for ADOA?Can Autosomal Dominant Optic Atrophy Skip a Generation?Can You Drive With Autosomal Dominant Optic Atrophy?Do Hormones Worsen ADOA Vision Loss in Teenage Girls?Do Prematurity and Birth Weight Affect ADOA Symptoms?How Does Blue-Yellow Color Blindness Present in ADOA?How Does Smoking Affect Vision Loss in ADOA Patients?How is ADOA Differentiated from Normal Tension Glaucoma?Why is ADOA Misdiagnosed as a Lazy Eye in Children?ADOA vs. LHON: What Are the Key Differences?What Foods to Avoid With Autosomal Dominant Optic Atrophy?What Do ADOA Central Blind Spots Look Like? | Inciteful MedWhat Does an OCT Scan Show in ADOA? | Inciteful MedWhat If OPA1 Genetic Testing Is Negative For ADOA?What is the STK-002 Clinical Trial for ADOA?When Does Hearing Loss Start in ADOA-Plus Syndrome?What Medications to Avoid with ADOA?What Support Groups and Registries Exist for ADOA?What Should I Ask a Neuro-Ophthalmologist About ADOA?

References

References (32)
  1. 1

    Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the OPA1 Gene.

    García-López M, Jiménez-Vicente L, González-Jabardo R, et al.

    International journal of molecular sciences 2024; (25(13)) doi:10.3390/ijms25137240.

    PMID: 39000346
  2. 2

    Dominant optic atrophy: Culprit mitochondria in the optic nerve.

    Lenaers G, Neutzner A, Le Dantec Y, et al.

    Progress in retinal and eye research 2021; (83()):100935 doi:10.1016/j.preteyeres.2020.100935.

    PMID: 33340656
  3. 3

    The reduction of temporal optic nerve head microcirculation in autosomal dominant optic atrophy.

    Inoue M, Himori N, Kunikata H, et al.

    Acta ophthalmologica 2016; (94(7)):e580-e585 doi:10.1111/aos.12999.

    PMID: 26936288
  4. 4

    Short Wavelength Automated Perimetry, Standard Automated Perimetry, and Optical Coherence Tomography in Dominant Optic Atrophy.

    Lombardo M, Cusumano A, Mancino R, et al.

    Journal of clinical medicine 2024; (13(7)) doi:10.3390/jcm13071971.

    PMID: 38610740
  5. 5

    Clinical and Genetic Findings in an Autosomal Dominant Optic Atrophy-Compatible Phenotype Harboring an OPA1 Variant: A Case Report.

    Murati Calderon RA, Landestoy G, Izquierdo N

    Cureus 2025; (17(10)):e95622 doi:10.7759/cureus.95622.

    PMID: 41322916
  6. 6

    Assessment of the retinal posterior pole in dominant optic atrophy by spectral-domain optical coherence tomography and microperimetry.

    Cesareo M, Ciuffoletti E, Martucci A, et al.

    PloS one 2017; (12(3)):e0174560 doi:10.1371/journal.pone.0174560.

    PMID: 28358911
  7. 7

    Disrupted energy metabolism is associated with retinal ganglion cell degeneration in autosomal dominant optic atrophy.

    Kang EY, Tseng YJ, Peng WH, et al.

    Science advances 2026; (12(8)):eadx7815 doi:10.1126/sciadv.adx7815.

    PMID: 41706861
  8. 8

    OPA1 and disease-causing mutants perturb mitochondrial nucleoid distribution.

    Macuada J, Molina-Riquelme I, Vidal G, et al.

    Cell death & disease 2024; (15(11)):870 doi:10.1038/s41419-024-07165-9.

    PMID: 39616197
  9. 9

    Correlation between quality of vision and clinical and structural parameters in patients with Autosomal Dominant Optic Atrophy.

    Camós-Carreras A, Figueras-Roca M, Albà-Arbalat S, et al.

    Eye (London, England) 2025; (39(9)):1837-1842 doi:10.1038/s41433-025-03762-w.

    PMID: 40140688
  10. 10

    Optical coherence tomography angiography in the multimodal assessment of the retinal posterior pole in autosomal dominant optic atrophy.

    Cesareo M, Giannini C, Di Marino M, et al.

    Acta ophthalmologica 2022; (100(3)):e798-e806 doi:10.1111/aos.14972.

    PMID: 34250739
  11. 11

    Autosomal dominant optic atrophy plus due to the novel OPA1 variant c.1463G>C.

    Finsterer J, Laccone F

    Metabolic brain disease 2019; (34(4)):1023-1027 doi:10.1007/s11011-019-00425-0.

    PMID: 31152339
  12. 12

    Biallelic Optic Atrophy 1 (OPA1) Related Disorder-Case Report and Literature Review.

    Othman BA, Ong JE, Dumitrescu AV

    Genes 2022; (13(6)) doi:10.3390/genes13061005.

    PMID: 35741767
  13. 13

    Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy.

    Ham M, Han J, Osann K, et al.

    Mitochondrion 2019; (46()):262-269 doi:10.1016/j.mito.2018.07.006.

    PMID: 30165240
  14. 14

    A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family.

    Ahmad KE, Davis RL, Sue CM

    Journal of neurology 2015; (262(10)):2323-8 doi:10.1007/s00415-015-7849-6.

    PMID: 26194196
  15. 15

    Neuroradiological findings expand the phenotype of OPA1-related mitochondrial dysfunction.

    Roubertie A, Leboucq N, Picot MC, et al.

    Journal of the neurological sciences 2015; (349(1-2)):154-60.

    PMID: 25641387
  16. 16

    OPA1 mutation affects autophagy and triggers senescence in autosomal dominant optic atrophy plus fibroblasts.

    Zanfardino P, Amati A, Doccini S, et al.

    Human molecular genetics 2024; (33(9)):768-786 doi:10.1093/hmg/ddae008.

    PMID: 38280232
  17. 17

    Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy.

    Ahuja AS, Selvam P, Vadlamudi C, et al.

    Ophthalmic genetics 2020; (41(6)):563-569 doi:10.1080/13816810.2020.1814344.

    PMID: 32940104
  18. 18

    OPA1 disease-causing mutants have domain-specific effects on mitochondrial ultrastructure and fusion.

    Cartes-Saavedra B, Lagos D, Macuada J, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2023; (120(12)):e2207471120 doi:10.1073/pnas.2207471120.

    PMID: 36927155
  19. 19

    Contrasting pathophysiological mechanisms of OPA1 mutations in autosomal dominant optic atrophy.

    Yao SQ, Liang JJ, Zhou H, et al.

    Cell death discovery 2025; (11(1)):259 doi:10.1038/s41420-025-02442-8.

    PMID: 40447565
  20. 20

    Optimized OPA1 Isoforms 1 and 7 Provide Therapeutic Benefit in Models of Mitochondrial Dysfunction.

    Maloney DM, Chadderton N, Millington-Ward S, et al.

    Frontiers in neuroscience 2020; (14()):571479 doi:10.3389/fnins.2020.571479.

    PMID: 33324145
  21. 21

    Mitochondrial disorders of the retinal ganglion cells and the optic nerve.

    Finsterer J, Mancuso M, Pareyson D, et al.

    Mitochondrion 2018; (42()):1-10 doi:10.1016/j.mito.2017.10.003.

    PMID: 29054473
  22. 22

    Mitochondrial optic neuropathies.

    Carelli V, La Morgia C, Yu-Wai-Man P

    Handbook of clinical neurology 2023; (194()):23-42 doi:10.1016/B978-0-12-821751-1.00010-5.

    PMID: 36813316
  23. 23

    Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation.

    Chun BY, Rizzo JF

    Current opinion in ophthalmology 2016; (27(6)):475-480 doi:10.1097/ICU.0000000000000314.

    PMID: 27585216
  24. 24

    Genotype-phenotype heterogeneity of ganglion cell and inner plexiform layer deficit in autosomal-dominant optic atrophy.

    Rönnbäck C, Nissen C, Almind GJ, et al.

    Acta ophthalmologica 2015; (93(8)):762-6 doi:10.1111/aos.12835.

    PMID: 26385429
  25. 25

    A Missense Mutation in OPA1 Causes Dominant Optic Atrophy in a Chinese Family.

    Mei S, Huang X, Cheng L, et al.

    Journal of ophthalmology 2019; (2019()):1424928 doi:10.1155/2019/1424928.

    PMID: 31781369
  26. 26

    Vision-related quality of life and visual ability in patients with autosomal dominant optic atrophy.

    Eckmann-Hansen C, Bek T, Sander B, Larsen M

    Acta ophthalmologica 2022; (100(7)):797-804 doi:10.1111/aos.15102.

    PMID: 35146926
  27. 27

    Case of autosomal dominant optic atrophy with relatively good visual function.

    Tachibana M, Hayashi T, Igawa Y, et al.

    BMC ophthalmology 2025; (25(1)):443 doi:10.1186/s12886-025-04276-5.

    PMID: 40751186
  28. 28

    Clinical and Structural Parameters in Autosomal Dominant Optic Atrophy Patients: A Cross-Sectional Study Using Optical Coherence Tomography.

    Camós-Carreras A, Figueras-Roca M, Albà-Arbalat S, et al.

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2024; (45(3)):273-277 doi:10.1097/WNO.0000000000002294.

    PMID: 39805076
  29. 29

    Comparison of the clinical and genetic features of autosomal dominant optic atrophy and normal tension glaucoma in young Chinese adults.

    Zhang Y, Sun X, Tian G, Chen Y

    Eye (London, England) 2023; (37(4)):624-630 doi:10.1038/s41433-022-01990-y.

    PMID: 35273349
  30. 30

    Genotype-phenotype and OCT correlations in Autosomal Dominant Optic Atrophy related to OPA1 gene mutations: Report of 13 Italian families.

    Pretegiani E, Rosini F, Rufa A, et al.

    Journal of the neurological sciences 2017; (382()):29-35 doi:10.1016/j.jns.2017.09.018.

    PMID: 29111013
  31. 31

    CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs.

    Sladen PE, Perdigão PRL, Salsbury G, et al.

    Molecular therapy. Nucleic acids 2021; (26()):432-443 doi:10.1016/j.omtn.2021.08.015.

    PMID: 34589289
  32. 32

    Autosomal dominant optic atrophy caused by six novel pathogenic OPA1 variants and genotype-phenotype correlation analysis.

    Han J, Li Y, You Y, et al.

    BMC ophthalmology 2022; (22(1)):322 doi:10.1186/s12886-022-02546-0.

    PMID: 35883160

This page provides educational information about visual prognosis and blindness risks in ADOA. It does not replace professional medical advice. Always consult your ophthalmologist or neuro-ophthalmologist regarding your specific vision and disease progression.

Get notified when new evidence is published on Autosomal dominant optic atrophy, classic form.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.